Delve into the complex landscape of non-Hodgkin lymphoma research, where a cure is pursued amidst a backdrop of over 100 subtypes of this disease.
In this episode, Dr. Kieron Dunleavy, of MedStar Georgetown University Hospital, breaks down the differences in treatments, prognosis and goals for both slow-growing and aggressive subtypes of non-Hodgkin lymphoma. Discover the remarkable momentum of scientific progress that increased the understanding and management of lymphoma, igniting a renewed sense of hope for patients and their loved ones.
Podcast: Play in new window | Download
Subscribe: Google Podcasts | Spotify | Pandora | Blubrry | JioSaavn | Podchaser | More
CLICK HERE to participate in our episode survey.Mentioned on this episode:
- Non-Hodgkin lymphoma
- Chronic lymphocytic leukemia
- POLARIX study
- Stem Cell Transplantion
- CAR T-cell Therapy
- ZUMA-7 Study
- TRANSFORM Study
- Graft-vs-host Disease (GVHD)
- Minimal/Measurable Residual Disease (MRD)
- Clinical Trial Support Center
Additional LLS Support Resources:
- Information Specialists
- Free telephone/web patient programs
- Free booklets
- Financial support
- Caregiver support
- Young Adult Resources
- Survivorship Workbook
- Online chats
- LLS Community
- Support groups
- Patti Robinson Kaufmann First Connection Program
- Free Nutrition Consultations
Support for this episode provided by: Eli Lilly and Company and Genentech, Inc. & Biogen.
I was diagnosed with T-cell/histiocyte rich DLBCL. It was interesting to listening this podcast and easy way to understand the topic as someone like me newly diagnosed. Looking forward to listen to more podcasts and maybe in the future about rare type of T-cell/histiocyte rich DLBCL.